Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 4/20 | 0.62 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8266537 | 0.89 | TNFRSF1A (0.56) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7107701 | 0.87 | HSD17B1 (0.56) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL27159530 | 0.85 | APP (0.81) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL32677328 | 0.85 | APP (0.81) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31310542 | 0.84 | NPC1 (0.56) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1665299 | 0.84 | NPC1 (0.56) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7641051 | 0.83 | APP (0.58) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL24860537 | 0.82 | NPC1 (0.49) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14832893 | 0.82 | NPC1 (0.49) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL6832572 | 0.81 | ESR1 (0.58) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395769-B1 | ACTIVATION ESTROGEN; THERAPY FOR OSTEOPOROSIS, ANTILIPEMIC AGENTS | ELI LILLY AND COMPANY | 2002-05-28 | — | — | US | claimed |
| US-6096781-A | 2-PHENYL-1-BENZOTHIOPHENE DERIVATIVES ARE USEFUL FOR TREATMENT OF OSTEOPOROSIS AND HYPERLIPEMIA | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | claimed |
| EP-0920862-A1 | 2-Arylbenzo b thiophenes useful for the treatment of estrogen deprivation syndrome | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | claimed |
| EP-3162806-B1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | LT MATERIALS CO LTD (KR) | 2023-08-23 | — | — | EP | disclosed |
| CN-110483475-B | Method for preparing benzothiophene compound by silver oxide catalysis method | 绍兴文理学院 | 2020-11-27 | — | — | CN | disclosed |
| US-10644244-B2 | Heterocyclic compound and organic light emitting device using same | LT MATERIALS CO., LTD. (KR) | 2020-05-05 | — | — | US | disclosed |
| CN-110483475-A | A kind of method that silver oxide catalysis method prepares benzothiophenes | UNIV SHAOXING | 2019-11-22 | — | — | CN | disclosed |
| CN-107406424-A | Estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2017-11-28 | — | — | CN | disclosed |
| US-20170141325-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | HEESUNG MATERIAL LTD. (KR) | 2017-05-18 | — | — | US | disclosed |
| EP-3162806-A2 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | Heesung Material Ltd. (KR) | 2017-05-03 | — | — | EP | disclosed |
| EP-1027051-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-01-05 | — | — | EP | disclosed |
| EP-0920862-A1 | 2-Arylbenzo b thiophenes useful for the treatment of estrogen deprivation syndrome | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0863755-A4 | ANTITHROMBOTIC DIAMINES | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0863755-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4024273-A | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4001426-A | HAVING CORONARY VASODILATOR ACTIVITY | SMITHKLINE CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3983245-A | CORONARY VASODILATORS | SMITHKLINE CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
| US-3947470-A | CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170141325-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | CRY1, CRY2, CYBA | RAB9A 3913/4885NPC1 4299/4885SMN1; SMN2 3827/4885 |
| US-10644244-B2 | Heterocyclic compound and organic light emitting device using same | CRY1, CRY2, CYBA | RAB9A 3913/4885NPC1 4299/4885SMN1; SMN2 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.